The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Institute for Clinical Economic Review Final Report on RA Treatments

Institute for Clinical Economic Review Final Report on RA Treatments

May 4, 2017 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid arthritis (RA), as well as the comparative value of these therapies in terms of cost effectiveness.1

You Might Also Like
  • Blue Ribbon Panel on Academic Rheumatology Publishes Final Report
  • Opinion: Help Bring Drug Prices Down
  • National Institute of Arthritis & Musculoskeletal & Skin Diseases Report for 2015
Explore This Issue
June 2017
Also By This Author
  • Does the Metal-Fatigue Principle Apply to Elderly Bones?

 A Flawed Report?
The good news from the report: TIMs are highly effective in treating moderate to severe RA. Their life-changing effects for RA patients were emphasized by ICER President Seven D. Pearson, MD, in a press release accompanying the report’s publication.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, the report also found that none of the TIMs was considered cost effective based on the methodology used in the report.

This latter finding is generating considerable concern among rheumatologists and patient advocacy groups who fear that any documented analysis showing the use of these expensive drugs is not cost effective may interfere with patient access to these drugs and may, ultimately, be used to set policy and formulary decisions.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The ICER report is basically flawed in that the methodology and analysis do not cohere with the ACR and EULAR guidelines on RA treatment with TIMs,” says Elizabeth A. Tindall, MD, a rheumatologist from Rheumatology Consultants of Oregon LLC, who reviewed and commented on drafts of the report before its final publication. “This would limit patient access to many RA therapies.”

Guy Eakin, PhD, senior vice president of scientific strategy for the Arthritis Foundation (AF), acknowledged the flaws in the methodology used in the report, specifically questioning the patient population used in the study to generate the cost-effectiveness analysis, which he thinks is not representative of the true patient population with RA. However, Dr. Eakin, who worked closely with ICER in developing the report, commended the ICER report for its transparency in tackling the difficult issue of cost of these expensive medications.

Report Basis, Findings, Recommendations
The ICER report was based on an analysis of data from 67 randomized clinical studies and 17 observational studies on the use of 11 TIMs (or biologics) either as monotherapy or in combination with conventional disease-modifying anti-rheumatic drugs (DMARDs) to treat patients with moderate to severe RA. Included in the analysis were nine TIMs approved by the Food and Drug Administration (FDA) for RA, as well as two investigational TIMs still awaiting FDA approval (Table 1).1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Drug Updates, Practice Management, Professional Topics, Rheumatoid Arthritis Tagged With: Institute for Clinical and Economic Review (ICER), targeted immune modulators (TIMs), Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & ValueIssue: June 2017

You Might Also Like:
  • Blue Ribbon Panel on Academic Rheumatology Publishes Final Report
  • Opinion: Help Bring Drug Prices Down
  • National Institute of Arthritis & Musculoskeletal & Skin Diseases Report for 2015
  • 6 Tips for Writing a Good Clinical Case Report

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)